Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 23 06 2020
accepted: 30 10 2020
pubmed: 6 11 2020
medline: 14 8 2021
entrez: 5 11 2020
Statut: ppublish

Résumé

The urinary antigen test (UAT) is a rapid diagnostic method for pneumococcal pneumonia, but the high false-negative rate of 30% may affect its reliability. To maximize the utility of UAT, it is necessary to investigate the patient factors affecting UAT results. However, there is no report elucidating the association between its utility and pre-existing lung abnormalities. We retrospectively reviewed 388 patients with pneumococcal pneumonia confirmed by blood and/or sputum culture tests. Finally, 94 of 388 patients who had the results of UAT and computed tomography scans were enrolled to evaluate the association between the utility of UAT and patient factors including pulmonary emphysema and fibrosis. The overall positive rate of UAT was 69.1%. The positive rates of UAT in the patients with emphysema were significantly lower than those in individuals without emphysema (33.3% and 77.6%, p < 0.001). Univariate logistic regression analysis showed that the presence of emphysema was associated with a low positive rate (odds ratio 6.944, 95% confidence interval 2.268-21.231). Multivariate logistic analysis showed that the presence of emphysema and lower levels of serum blood urea nitrogen (BUN) were significantly and independently associated with a low positive rate. The combination of emphysema and BUN can potentially stratify the positive rate of UAT in patients with pneumococcal pneumonia. Patients with pneumococcal pneumonia and emphysema have a lower positive rate of UAT. Additionally, the combination of emphysema and serum BUN value may be useful to evaluate the reliability of the negative results of pneumococcal UAT.

Identifiants

pubmed: 33150516
doi: 10.1007/s10096-020-04095-0
pii: 10.1007/s10096-020-04095-0
doi:

Substances chimiques

Antigens, Bacterial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

871-877

Références

File TM (2003) Community-acquired pneumonia. Lancet (London, England) 362(9400):1991–2001
doi: 10.1016/S0140-6736(03)15021-0
Dominguez J, Gali N, Blanco S, Pedroso P, Prat C, Matas L, Ausina V (2001) Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 119(1):243–249
doi: 10.1378/chest.119.1.243
Molinos L, Zalacain R, Menendez R, Reyes S, Capelastegui A, Cilloniz C, Rajas O, Borderias L, Martin-Villasclaras JJ, Bello S, Alfageme I, Rodriguez de Castro F, Rello J, Ruiz-Manzano J, Gabarrus A, Musher DM, Torres A (2015) Sensitivity, specificity, and positivity predictors of the pneumococcal urinary antigen test in community-acquired pneumonia. Annals of the American Thoracic Soc 12(10):1482–1489
doi: 10.1513/AnnalsATS.201505-304OC
Sordé R, Falcó V, Lowak M, Domingo E, Ferrer A, Burgos J, Puig M, Cabral E, Len O, Pahissa A (2011) Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 171(2):166–172
doi: 10.1001/archinternmed.2010.347
Murdoch DR, Laing RT, Mills GD, Karalus NC, Town GI, Mirrett S, Reller LB (2001) Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 39(10):3495–3498
doi: 10.1128/JCM.39.10.3495-3498.2001
Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, Mirete C, Royo G, Hidalgo AM (2003) Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 36(3):286–292
doi: 10.1086/345852
Dusemund F, Chronis J, Baty F, Albrich WC, Brutsche MH (2014) The outcome of community-acquired pneumonia in patients with chronic lung disease: a case-control study. Swiss Med Wkly 144:w14013
pubmed: 25184329
Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, Miyahara Y, Kagiyama N, Kurashima K, Yanagisawa T, Sugita Y (2013) Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Internal Med (Tokyo, Japan) 52(3):317–324
doi: 10.2169/internalmedicine.52.8830
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG (2019) Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 200(7):e45–e67
doi: 10.1164/rccm.201908-1581ST
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336(4):243–250
doi: 10.1056/NEJM199701233360402
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5):377–382
doi: 10.1136/thorax.58.5.377
Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458
doi: 10.1038/bmt.2012.244
Watanabe H, Uruma T, Tazaki G, Kikuchi R, Tsuji T, Itoh M (2015) Clinical factors associated with negative urinary antigen tests implemented for the diagnosis of community-acquired pneumococcal pneumonia in adult patients. Med Princ Pract 24(2):189–194
doi: 10.1159/000369931
Sakao S, Voelkel NF, Tatsumi K (2014) The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations. Eur Respir Rev 23(133):350–355
doi: 10.1183/09059180.00007913
Andreo F, Ruiz-Manzano J, Prat C, Lores L, Blanco S, Malet A, Gallardo X, Dominguez J (2010) Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. Respir Med 104(3):397–403
doi: 10.1016/j.rmed.2009.10.013
Jover F, Cuadrado JM, Andreu L, Martinez S, Canizares R, de la Tabla VO, Martin C, Roig P, Merino J (2008) A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med 19(1):15–21
doi: 10.1016/j.ejim.2007.03.015
Camou F, Issa N, Bessede E, Mourissoux G, Guisset O (2015) Usefulness of pneumococcal antigen urinary testing in the intensive care unit? Med Mal Infect 45(8):318–323
doi: 10.1016/j.medmal.2015.08.002
Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratala J, Chang FY, Charles PG, Diaz AA, Dominguez J, Ehara N, Endeman H, Falco V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Marekovic I, Masia M, Matta MA, Miro O, Murdoch DR, Nuermberger E, Paolini R, Perello R, Snijders D, Plecko V, Sorde R, Stralin K, van der Eerden MM, Vila-Corcoles A, Watt JP (2013) Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 8(4):e60273
doi: 10.1371/journal.pone.0060273
Smith MD, Derrington P, Evans R, Creek M, Morris R, Dance DA, Cartwright K (2003) Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 41(7):2810–2813
doi: 10.1128/JCM.41.7.2810-2813.2003

Auteurs

Erika Kobayashi (E)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kakuhiro Yamaguchi (K)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. yamaguchikakuhiro@gmail.com.

Rie Nagaoka (R)

Division of Clinical Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Shinjiro Sakamoto (S)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Yasushi Horimasu (Y)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Takeshi Masuda (T)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Shintaro Miyamoto (S)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Taku Nakashima (T)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Hiroshi Iwamoto (H)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Kazunori Fujitaka (K)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Michiya Yokozaki (M)

Division of Clinical Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.

Hiroki Ohge (H)

Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan.

Hironobu Hamada (H)

Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Noboru Hattori (N)

Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH